Cardiff Oncology Reports Third Quarter 2025 Results and Provides Business Update

– Announced positive data from the ongoing Phase 2 CRDF-004 trial evaluating onvansertib + standard of care for the treatment of first-line RAS-mutated metastatic colorectal cancer –

Read more at globenewswire.com